Immunogenic Compositions Of Staphylococcus Epidermidis Polypeptide Antigens

Abstract

The present invention relates to immunogenic compositions, comprising polypeptides isolated from Staphylococcus epidermidis . The invention also relates to polynucleotides encoding Staphylococcus epidermidis polypeptides and their use in immunogenic compositions. In addition, the invention relates to methods of inducing an immune response in mammals against Staphylococcus epidermidis and Staphylococcus aureus using immunogenic compositions of the Staphylococcus epidermidis polypeptides and polynucleotides. The invention also relates to methods for detecting Staphylococcus epidermidis in a biological sample.

1 - 29 . (canceled) 
     
     
         30 . A method of inducing an immune response against  Staphylococcus epidermidis  or  Staphylococcus aureus  comprising administering to a mammal an immunogenic amount of a composition comprising an isolated polypeptide having at least about 95% identity to an amino acid sequence chosen from one or more of SEQ ID NO: 1 through SEQ ID NO: 32 or a biological equivalent thereof, or a fragment thereof, and a pharmaceutically acceptable carrier. 
     
     
         31 . The method of  claim 30 , wherein the polypeptide further comprises heterologous amino acids. 
     
     
         32 . The method of  claim 31 , wherein the polypeptide is a fusion polypeptide. 
     
     
         33 . The method of  claim 30 , wherein the composition further comprises an adjuvant. 
     
     
         34 . The method of  claim 30 , wherein the polypeptide is a recombinant polypeptide. 
     
     
         35 . A method of inducing an immune response against  Staphylococcus epidermidis  or  Staphylococcus aureus  comprising administering to a mammal an immunogenic amount of a composition comprising an isolated polypeptide encoded by a polynucleotide having at least about 95% identity to a nucleotide sequence chosen from one or more of SEQ ID NO: 33 through SEQ ID NO: 64, a degenerate variant thereof, or a fragment thereof and a pharmaceutically acceptable carrier. 
     
     
         36 - 37 . (canceled) 
     
     
         38 . The method of  claim 35 , wherein the polynucleotide is a recombinant polynucleotide. 
     
     
         39 . The method of  claim 35 , wherein the polynucleotide further comprises heterologous nucleotides. 
     
     
         40 . (canceled) 
     
     
         41 . The method of  claim 35 , wherein the composition further comprises an adjuvant. 
     
     
         42 . The method of  claim 35 , wherein said composition further comprises a transfection facilitating agent. 
     
     
         43 . The method of  claim 42 , wherein said transfection facilitating agent is bupivicaine. 
     
     
         44 - 48 . (canceled) 
     
     
         49 . The method of  claim 30 , wherein said polypeptide has an amino acid sequence chosen from one or more of SEQ ID NO: 1 through SEQ ID NO: 32. 
     
     
         50 . The method of  claim 35 , wherein said polynucleotide has a nucleotide sequence chosen from one or more of SEQ ID NO: 33 through SEQ ID NO: 64.